Effectiveness of second-line sunitinib after immunotherapy in metastatic kidney cancer

There is very little information on the effectiveness of sunitinib (a vascular endothelial growth factor (VEGF) inhibitor) as a second-line treatment after first-line treatment with immunotherapy for patients with metastatic renal cell carcinoma (RCC). A study published in Clinical Genitourinary Cancer last month looked at 102 patients in a real-world setting who were treated with sunitinib after having immunotherapy or immunotherapy combinations as their first treatment. Most patients had intermediate (54%) or poor risk (36%) disease.

Average overall survival for these patients was 15.6 months, with a 1-year survival rate of 57.5%. Sunitinib shrank the cancer in 22.5% of patients and the average time on treatment was 5.4 months.

Despite the availability of effective first-line treatments in recent years, second-line sunitinib continues to be effective after failure of immunotherapy. Further studies are needed to confirm the optimal sequence of treatments for metastatic RCC.

Read more in UroToday here

Share this Post!

Related post